- Healthcare providers are being urged to use HAAD’s e-Notification system to input ‘adverse reaction’ and ‘medication error’ reports related to medications and vaccinations
- HAAD is implementing its pharmacovigilance programme to ensure the quality and safety of all drugs available to Abu Dhabi residents
- The programme looks to facilitate desirable therapeutic outcomes during patients’ treatment, for their overall journey to health
This announcement is part of HAAD’s Pharmacovigilance programme, which was primarily implemented to monitor adverse reactions to drugs and minimize the occurrence of medication errors throughout the Emirate. The following encompass all reportable cases: unintended adverse effects, drug misuse, overdose, interactions (including drug-drug and drug-food interactions) and any unusual lack of therapeutic efficacy.
It is worth mentioning that, the HAAD Pharmacovigilance programme has been operational since June 2008.
HAAD revealed that it has received 616 ‘adverse reaction’ reports and 1102 ‘medication error’ reports during 2016. (See figure below)
Figure 1. Adverse Reactions and Medication Errors Reporting Trend for year 2016
According to statistics presented by HAAD’s Pharmacovigilance program for the period 2013-2015: antibiotics class of drugs was the greatest cause of adverse reactions, with a 47% prevalence rate; followed by 19% for anti-inflammatory medications; and, 5% each for painkillers and gastrointestinal drugs. (See figure below)
Figure 2. Distribution of of Suspected Drugs by Therapeutic Category for 2013-2015
Physicians submitted the greatest number of reports on adverse reactions, followed by Pharmacists and nurses. On the other hand, Pharmacists were the group to report the greatest number of medication errors.
Dr. Khaled Al Jaberi, Director of Health Regulation Division at HAAD, stated: “In order to simplify and standardize communication channels, and operate within a unified database for communication, we encourage all healthcare providers to use the e-Notification system in order to facilitate reporting, enable centralized data storage and simplify data analysis. Our pharmacovigilance team will spare no effort in raising awareness about the e-Notification system, as well as its optimal form of use, by offering training courses to healthcare practitioners where and when needed.”
Nevertheless, if healthcare providers are unable to submit their reports via the e-Notification system, HAAD urges submission through various other permissible means, including e-mail, fax or even hand-delivery.
Al Jaberi added: “In our efforts to improve the quality and safety of healthcare services and standards, and enhance the overall patient experience, HAAD is looking to implement a robust pharmacovigilance programme capable of ensuring the quality and safety of all drugs available to the residents of Abu Dhabi Emirate. We see the programme facilitating desirable therapeutic outcomes during a patient’s treatment, and maintaining a delicate balance between the potential health benefits and the risks associated with administering medications.”
- Ends -